CN105061433A - Synthetic method for 5-bromo-imidazo[1, 2-A]pyrimidine-3-carboxylate and corresponding acid thereof - Google Patents
Synthetic method for 5-bromo-imidazo[1, 2-A]pyrimidine-3-carboxylate and corresponding acid thereof Download PDFInfo
- Publication number
- CN105061433A CN105061433A CN201510444388.9A CN201510444388A CN105061433A CN 105061433 A CN105061433 A CN 105061433A CN 201510444388 A CN201510444388 A CN 201510444388A CN 105061433 A CN105061433 A CN 105061433A
- Authority
- CN
- China
- Prior art keywords
- pyrimidine
- bromo
- imidazo
- synthetic method
- class
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC(*)=C[*@@]1C(N)=C*=C1*=C Chemical compound CC(*)=C[*@@]1C(N)=C*=C1*=C 0.000 description 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
The invention discloses a synthetic method for for 5-bromo-imidazo[1, 2-A]pyrimidine-3-carboxylate and corresponding acid thereof. The synthetic method comprises: taking a compound as shown in formula (1) as a raw material, and reacting the raw material with a compound as shown in formula (2) to generate a compound as shown in formula (3); and reacting the compound as shown in formula (3) with alpha ester of halogenated acid, and purifying to obtain the 5-bromo-imidazo[1, 2-a]pyrimidine-3-carboxylate; and hydrolyzing and acidifying the 5-bromo-imidazo[1, 2-a]pyrimidine-3-carboxylate to obtain 5-bromo-imidazo[1, 2-a]pyrimidine-3-carboxylic acid. The synthetic method disclosed by the invention is short in synthesis route and high in yield, and raw materials are easily available.
Description
Technical field
The present invention relates to Minute Organic Synthesis technical field, particularly the synthetic method of a class 5-bromo-imidazo [1,2-A] pyrimidine-3-carboxylicesters and respective acids thereof.
Background technology
Imidazo [1,2-A] pyrimidine carboxylic compounds is the very important nitrogenous fused heterocyclic compound of a class, because its specific physiologically active becomes the study hotspot of organic chemist and Pharmaceutical Chemist.Many imidazos [1,2-A] pyrimidine carboxylic compounds has to many target enzymes etc. that obvious inhibition has antiviral, antibacterium, antimicrobial and anti-cell mitogen active, imidazo [1,2-A] pyrimidine carboxylic compounds is also used to the research of medicine particularly in treatment tumour of stomach ulcer, diabetes and psychosis etc.Such as imidazo [1,2-A] pyrimidine carboxylic compounds is used to the research (JournalofMedicinalChemistry (2010), 53 (15), 5620-5628) of type ii diabetes.Research finds imidazo [1, 2-A] pyrimidine-3-carboxylicesters is at antituberculosis, reduce the aldehyde oxidase of metabolism, important meaning (Bioorganic & MedicinalChemistryLetters (2014) is had in the research of Gpbar1 receptor modulators, 24 (15), 3493-3498), (JournalofMedicinalChemistry (2011), 54 (21), 7705-7712), (PCTInt.Appl. (2013), WO2013057650A1Apr25, 2013), (PCTInt.Appl. (2012), WO2012143796A2Oct26, 2012).
The imidazo [1 of bibliographical information, 2-A] one of the synthetic method of pyrimidine-3-carboxylicesters and respective acids thereof adopts 2-aminopyrimidine and ethyl 2-bromo-3-carbonyl butyric ester back flow reaction 36 hours, then target product-Bioorganic & MedicinalChemistryLetters is obtained through lithium hydroxide basic hydrolysis and acidifying, 24 (15), 3493-3498,2014.
The imidazo [1 of bibliographical information, 2-A] another synthetic method of pyrimidine-3-carboxylicesters and respective acids thereof to react to NBS by 3-ethoxy ethyl acrylate and generates corresponding bromide, then react to 2-amino-5-methylpyrimidine and generate corresponding imidazo [1,2-A] pyrimidine-3-carboxylicesters, acid (JournalofMedicinalChemistry is obtained through hydrolysis and acidifying, 7705-7712,2011)
The imidazo [1 of bibliographical information, 2-A] another synthetic method of pyrimidine-3-carboxylicesters and respective acids thereof reacts the ethyl imidazol(e) that obtains respectively mixing also [1 in ethanol by 2-amino-5-methylpyrimidine and 3-BrPA ethyl ester, 2-A] pyrimidine-3-carboxylicesters and ethyl imidazol(e) also [1,2-A] pyrimidine-2-carboxylicesters (JournalofMedicinalChemistry, 5620-5628,2010).
Said synthesis route severe reaction conditions, reaction preference is poor, long reaction time, and yield is also lower.
Summary of the invention
For above-mentioned the deficiencies in the prior art, the invention provides the bromo-imidazo [1 of a class 5-, 2-A] synthetic method of pyrimidine-3-carboxylicesters and respective acids thereof, solve an existing class 5-bromo-imidazo [1,2-A] pyrimidine-3-carboxylicesters and respective acids severe reaction conditions thereof, problem that reaction yield is low.
Technical scheme of the present invention is achieved in that
The synthetic method of one class 5-bromo-imidazo [1,2-A] pyrimidine-3-carboxylicesters and respective acids thereof, comprises the following steps:
1) with formula (1) compound for raw material, react with formula (2) compound, production (3) compound;
2) formula (3) compound and alpha halo acid esters react, after purifying, obtain a class 5-bromo-imidazo [1,2-A] pyrimidine-3-carboxylicesters;
3) a class 5-bromo-imidazo [1,2-A] pyrimidine-3-carboxylicesters obtains a class 5-bromo-imidazo [1,2-A] pyrimidine-3-carboxylic acid through basic hydrolysis, acidifying;
Wherein, R
1for-H ,-F ,-Cl ,-Br ,-CN ,-CCH ,-NO
2,-OMe, C
1-C
4alkyl or C
3-C
5cycloalkyl; R
2for independently-H ,-F ,-Cl ,-Br ,-CN ,-CCH ,-NO
2,-OMe, C
1-C
4alkyl or C
3-C
5cycloalkyl; R
3for-H or C
1-C
4alkyl; X is-Cl ,-Br or-I; R
4for C
1-C
4alkyl.
Wherein, preferably, described formula (3) formula (3a) compound and formula (3b) compound composition, described formula (3a) compound is cis isomer, and described formula (3b) compound is trans isomer.
Wherein, preferably, described step 1) in reaction carry out in a solvent, solvent used be in methylene dichloride, 1,2-ethylene dichloride, chloroform, tetrahydrofuran (THF), ethyl acetate, acetonitrile, toluene, dimethylbenzene, ether, butanols and Virahol any one.
Wherein, preferably, described step 1) in reaction carry out under condition of no solvent.
Wherein, preferably, described step 1) in temperature of reaction be 0 ~ 80 DEG C.
Wherein, preferably, described step 1) method of purification of Chinese style (3) compound is extraction, recrystallization, underpressure distillation or column chromatography.
Wherein, preferably, described step 2) in reaction carry out in a solvent, solvent used is any one in methylene dichloride, chloroform, tetrahydrofuran (THF), ethyl acetate, acetonitrile, methyl alcohol, ethanol, propyl alcohol, Virahol, butanols, DMF and toluene; Described step 2) in temperature of reaction be 0 ~ 150 DEG C; Described step 2) in method of purification be extraction, recrystallization or column chromatography.
Wherein, preferably, described step 3) in temperature of reaction be 15 ~ 90 DEG C.
Wherein, preferably, described step 3) in base hydrolysis step alkali used be NaOH, KOH, LiOH or K
3pO
4; The acid used of described acidification step is hydrochloric acid, acetic acid or sulfuric acid.
Wherein, the chemistry of formula (2) compound is called DMF dimethylacetal (or ketone); Chemistry (E)-N'-(5-bromopyrimidin-2-yl)-N, the N-dimethylformimidamide by name of formula (3) compound.
Wherein, described formula (3) formula (3a) compound and formula (3b) compound composition, described formula (3a) compound is cis isomer, and described formula (3b) compound is trans isomer.
Beneficial effect of the present invention:
1. synthetic method synthetic route of the present invention is short, productive rate is high, raw material is easy to get.
2. synthesising method reacting condition of the present invention is gentle, and the reaction times is moderate, and process is easy to control, and aftertreatment is simple.
3. high, the many active function groups of reaction preference of the present invention does not need protection.
Embodiment
Be clearly and completely described the technical scheme in the embodiment of the present invention below, obviously, described embodiment is only the present invention's part embodiment, instead of whole embodiments.Based on the embodiment in the present invention, those of ordinary skill in the art, not making other embodiments all obtained under creative work prerequisite, belong to the scope of protection of the invention.
Embodiment 1
The present embodiment provides 5-bromine imidazo [1, the 2-A] pyrimidine-3-synthetic method of ethyl formate, and its structural formula is as follows:
N is added in the single necked round bottom flask of a 50ml, dinethylformamide dimethylacetal (10mL) and 2-amino-5-bromo pyrimi piperidine (3.46g, 20mmol) reflux stirring reaction 0.5 hour, TLC shows that reaction completes, obtain N, N-dimethyl-N'-2-(the bromo-pyrimidine of 5-) base-carbonamidine intermediate, rotary evaporation removes unnecessary DMF dimethylacetal, add N, dinethylformamide (DMF, 15mL), NaHCO
3(2.5g, 30mmol) and ethyl bromoacetate (5g, 30mmol), reflux 2 hours, reaction terminates, and is chilled to room temperature, adds 60mL water and 20mL extraction into ethyl acetate, separate organic phase, aqueous phase is extracted with ethyl acetate (3 × 20mL), merges organic phase, washes with water (2 × 15mL), the water washing of 20mL saturated common salt, anhydrous Na
2sO
4dry, filter, filtrate rotary evaporation obtains the thick product of 5-bromine imidazo [1,2-A] pyrimidine-3-ethyl formate except after desolventizing, this thick product is through normal hexane: the mixing solutions recrystallization of ethyl acetate=5:1 (volume ratio) obtains sterling 4.32g, productive rate 80%.
Wherein, step 2) in solvent used also can be in methylene dichloride, chloroform, tetrahydrofuran (THF), ethyl acetate, acetonitrile, methyl alcohol, ethanol, propyl alcohol, Virahol, butanols and toluene any one.Step 2) in the thick product of 5-bromine imidazo [1,2-A] pyrimidine-3-ethyl formate that obtains recrystallization or column chromatography also can be adopted to refine.
The present embodiment also provides 5-bromine imidazo [1, the 2-A] pyrimidine-3-synthetic method of formic acid, and its structural formula is as follows:
Add in a 50mL single port flask in 6-bromine imidazo [1,2-A] pyrimidine-3-ethyl formate (4.32g, 16mmol) and 20mL methyl alcohol, sodium hydroxide (1.92g, 48mmol) is dissolved in 5mL water, joins in reaction flask, stirred at ambient temperature 3h, TLC shows that reaction completes, and is neutralized to pH=4, suction filtration with the hydrochloric acid of 30%, the a small amount of water washing of filter cake, namely 5-bromine imidazo [1,2-A] pyrimidine-3-formic acid sterling 3.52g is obtained, productive rate 91% after drying.
Embodiment 2:
The present embodiment provides 5-bromine imidazo [1, the 2-A] pyrimidine-3-synthetic method of ethyl formate, and its structural formula is as follows:
N is added in the single necked round bottom flask of a 100ml, dinethylformamide dimethylacetal (50mL), 2-amino-5-bromo pyrimi piperidine (6.92g, 40mmol) with methylene dichloride (30ml), at room temperature stirring reaction 2h, TLC shows that reaction completes, obtain N, N-dimethyl-N'-2-(the bromo-pyrimidine of 5-) base-carbonamidine intermediate, rotary evaporation removes unnecessary N, dinethylformamide dimethylacetal, adds DMF (DMF, 25mL), NaHCO
3(6.72g, 80mmol) and ethyl bromoacetate (10g, 60mmol), reflux 1 hour, reaction terminates, and is chilled to room temperature, solution is transferred to the round-bottomed flask of a 250mL, add 80mL water and 30mL extraction into ethyl acetate, separate organic phase, aqueous phase is extracted with ethyl acetate (3 × 30mL), merge organic phase, wash with water (2 × 20mL), the water washing of 30mL saturated common salt, anhydrous Na
2sO
4dry, filter, filtrate rotary evaporation obtains the thick product of 5-bromine imidazo [1,2-A] pyrimidine-3-ethyl formate except after desolventizing, this thick product is through normal hexane: the mixing solutions recrystallization of ethyl acetate=5:1 (volume ratio) obtains sterling 7.31g, productive rate 67.5%.
Wherein, step 1 in the present embodiment) in solvent used also to can be in 1,2-ethylene dichloride, chloroform, tetrahydrofuran (THF), ethyl acetate, acetonitrile, toluene, dimethylbenzene, ether, butanols and Virahol any one.Step 1) N that obtains, N-dimethyl-N'-2-(the bromo-pyrimidine of 5-) base-carbonamidine intermediate method of purification also can adopt extraction, recrystallization or column chromatography.
The present embodiment also provides 5-bromine imidazo [1, the 2-A] pyrimidine-3-synthetic method of formic acid, and its structural formula is as follows:
6-bromine imidazo [1 is added in a 50mL single port flask, 2-A] pyrimidine-3-ethyl formate (7.31g, 27mmol) with in 20mL methyl alcohol, sodium hydroxide (3.24g, 81mmol) be dissolved in 5mL water, join in reaction flask, be heated to 90 DEG C of insulation reaction 5h, TLC shows that reaction completes, and is neutralized to pH=4, suction filtration with the hydrochloric acid of 30%, the a small amount of water washing of filter cake, namely 5-bromine imidazo [1,2-A] pyrimidine-3-formic acid sterling 5.72g is obtained, productive rate 87% after drying.
Embodiment 3:
The present embodiment provides 5-bromine imidazo [1, the 2-A] pyrimidine-3-synthetic method of ethyl formate, and its structural formula is as follows:
N is added in the single necked round bottom flask of a 500ml, dinethylformamide dimethylacetal 150mL) and 2-amino-5-bromo pyrimi piperidine (69.6g, 400mmol). at room temperature stirring reaction 2h, TLC show that reaction completes, obtain N, N-dimethyl-N'-2-(the bromo-pyrimidine of 5-) base-carbonamidine intermediate, rotary evaporation removes unnecessary DMF dimethylacetal, add N, dinethylformamide (DMF, 250mL), NaHCO
3(50g, 595mmol) and ethyl bromoacetate (97g, 580mmol), reflux 1 hour, reaction terminates, and is chilled to room temperature, adds 500mL water and 250mL extraction into ethyl acetate, separate organic phase, aqueous phase is extracted with ethyl acetate (3 × 80mL), merges organic phase, washes with water (2 × 50mL), the water washing of 50mL saturated common salt, anhydrous Na
2sO
4dry, filter, filtrate rotary evaporation obtains the thick product of 5-bromine imidazo [1,2-A] pyrimidine-3-ethyl formate except after desolventizing, this thick product is through normal hexane: the mixing solutions recrystallization of ethyl acetate=5:1 (volume ratio) obtains sterling 69.2g, productive rate 64%.
The present embodiment also provides 5-bromine imidazo [1, the 2-A] pyrimidine-3-synthetic method of formic acid, and its structural formula is as follows:
6-bromine imidazo [1 is added in a 500mL single port flask, 2-A] pyrimidine-3-ethyl formate (69.2g, 256mmol) with in 200mL methyl alcohol, sodium hydroxide (20.5g, 512mmol) be dissolved in 150mL water, join in reaction flask, stirred at ambient temperature reaction is spent the night, TLC shows that reaction completes, and is neutralized to pH=4, suction filtration with the hydrochloric acid of 30%, the a small amount of water washing of filter cake, namely 5-bromine imidazo [1,2-A] pyrimidine-3-formic acid sterling 58.4g is obtained, productive rate 94.2% after drying.
Wherein, step 3) in base hydrolysis step alkali used also can be KOH, LiOH or K
3pO
4; Acidification step acid used also can be acetic acid or sulfuric acid.
Embodiment 4
The present embodiment provides the chloro-5-of 4-bromo-6-cyanogen imidazo [1, the 2-A] pyrimidine-3-synthetic method of ethyl formate, and its structural formula is as follows:
Replace 2-amino-5-bromo pyrimi piperidine with the bromo-6-cyanopyrimidine of the chloro-5-of 2-amino-4-, replace DMF dimethylacetal with N,N-dimethylacetamide dimethylacetal, replace ethyl bromoacetate with ethyl chloroacetate.Other step, with embodiment 1, obtains sterling 5.32g, productive rate 78%.
The present embodiment also provides the synthetic method of the chloro-5-of 4-bromo-6-cyanogen imidazo [1,2-A] pyrimidine-3-formic acid, and its structural formula is as follows:
Its step, with embodiment 1, obtains the chloro-5-of 4-bromo-6-cyanogen imidazo [1,2-A] pyrimidine-3-formic acid 4.64g, productive rate: 90.2%.
Embodiment 5
The present embodiment provides 4-cyanogen-5-bromo-6-ethynyl imidazo [1, the 2-A] pyrimidine-3-synthetic method of methyl-formiate, and its structural formula is as follows:
With 2-amino-4-ethynyl--the bromo-6-nitro-pyrimidine of 5-replaces 2-amino-5-bromo pyrimi piperidine, replaces DMF dimethylacetal, replace ethyl bromoacetate with ethyl chloroacetate with N,N-dimethylacetamide dimethylacetal.Other step, with embodiment 2, obtains sterling 7.45g, productive rate 69%.
The present embodiment also provides the synthetic method of 4-cyanogen-5-bromo-6-ethynyl imidazo [1,2-A] pyrimidine-3-formic acid, and its structural formula is as follows:
Its step, with embodiment 2, obtains 4-cyanogen-5-bromo-6-ethynyl imidazo [1,2-A] pyrimidine-3-formic acid 6.91g, productive rate: 88.2%.
Embodiment 6
The present embodiment provides the synthetic method of the bromo-6-nitroimidazole of 5-also [1,2-A] pyrimidine-3-propyl formate, and its structural formula is as follows:
Replace 2-amino-5-bromo pyrimi piperidine with the bromo-6-nitro-pyrimidine of 2-amino-4-ethynyl-5-, replace DMF dimethylacetal with N,N-dimethylacetamide dimethylacetal, other step, with embodiment 3, obtains sterling 68.6g, productive rate 69.0%.
The present embodiment also provides the synthetic method of the bromo-6-nitroimidazole of 5-also [1,2-A] pyrimidine-3-formic acid, and its structural formula is as follows:
Its step, with embodiment 2, obtains the bromo-6-nitroimidazole of 5-also [1,2-A] pyrimidine-3-formic acid 57.6g, productive rate: 93.6%.
Embodiment 7
The present embodiment provides 4-nitro-5-bromo-6-methoxyl group imidazo [1, the 2-A] pyrimidine-3-synthetic method of butyl formate, and its structural formula is as follows:
Replace 2-amino-5-bromo pyrimi piperidine with the bromo-6-methoxy pyrimidine of 2-amino-4-nitro-5-, replace DMF dimethylacetal with N,N-dimethylacetamide dimethylacetal.Other step, with embodiment 1, obtains sterling 5.44g, productive rate 79%.
The present embodiment also provides the synthetic method of 4-nitro-5-bromo-6-methoxyl group imidazo [1,2-A] pyrimidine-3-formic acid, and its structural formula is as follows:
Its step, with embodiment 1, obtains 4-nitro-5-bromo-6-methoxyl group imidazo [1,2-A] pyrimidine-3-formic acid 4.58g, productive rate: 90.8%.
Embodiment 8
The present embodiment provides the synthetic method of the bromo-6-ethyl imidazol(e) of 4-methoxyl group-5-also [1,2-A] pyrimidine-3-ethyl formate, and its structural formula is as follows:
Replace 2-amino-5-bromo pyrimi piperidine with the bromo-6-ethyl-pyrimidine of 2-amino-4-methoxyl-5-, other step, with embodiment 2, obtains sterling 7.38g, productive rate 67.2%.
The present embodiment also provides the synthetic method of the bromo-6-ethyl imidazol(e) of 4-methoxyl group-5-also [1,2-A] pyrimidine-3-formic acid, and its structural formula is as follows:
Its step, with embodiment 2, obtains the bromo-6-ethyl imidazol(e) of 4-methoxyl group-5-also [1,2-A] pyrimidine-3-formic acid 6.85g, productive rate: 87.2%.
Embodiment 9
The present embodiment provides 4-ethyl-5-bromo-6-cyclobutyl imidazo [1, the 2-A] pyrimidine-3-synthetic method of ethyl formate, and its structural formula is as follows:
Replace 2-amino-5-bromo pyrimi piperidine with the bromo-6-cyclobutyl pyrimidines of 2-amino-4-ethyl-5-, other step, with embodiment 3, obtains sterling 70.2g, productive rate 70.8%.
The present embodiment also provides the synthetic method of 4-ethyl-5-bromo-6-cyclobutyl imidazo [1,2-A] pyrimidine-3-formic acid, and its structural formula is as follows:
Its step, with embodiment 2, obtains 4-ethyl-5-bromo-6-cyclobutyl imidazo [1,2-A] pyrimidine-3-formic acid 55.8g, productive rate: 91.2%.
Embodiment 10
The present embodiment provides 4-ethyl-5-bromo-6-cyclobutyl imidazo [1, the 2-A] pyrimidine-3-synthetic method of ethyl formate, and its structural formula is as follows:
Replace 2-amino-5-bromo pyrimi piperidine with the bromo-6-chloropyrimide of 2-amino-4-cyclobutyl-5-, other step, with embodiment 3, obtains sterling 69.5g, productive rate 70.1%.
The present embodiment also provides the synthetic method of 4-ethyl-5-bromo-6-cyclobutyl imidazo [1,2-A] pyrimidine-3-formic acid, and its structural formula is as follows:
Its step, with embodiment 2, obtains 4-ethyl-5-bromo-6-cyclobutyl imidazo [1,2-A] pyrimidine-3-formic acid 56.2g, productive rate: 90.8%.
The foregoing is only preferred embodiment of the present invention, not in order to limit the present invention, within the spirit and principles in the present invention all, any amendment done, equivalent replacement, improvement etc., all should be included within protection scope of the present invention.
Claims (8)
1. the synthetic method of a class 5-bromo-imidazo [1,2-A] pyrimidine-3-carboxylicesters and respective acids thereof, is characterized in that, comprise the following steps:
1) with formula (1) compound for raw material, react with formula (2) compound, production (3) compound;
2) formula (3) compound and alpha halo acid esters react, after purifying, obtain a class 5-bromo-imidazo [1,2-A] pyrimidine-3-carboxylicesters;
3) a class 5-bromo-imidazo [1,2-A] pyrimidine-3-carboxylicesters obtains a class 5-bromo-imidazo [1,2-A] pyrimidine-3-carboxylic acid through basic hydrolysis, acidifying;
Wherein, R
1for-H ,-F ,-Cl ,-Br ,-CN ,-CCH ,-NO
2,-OMe, C
1-C
4alkyl or C
3-C
5cycloalkyl; R
2for independently-H ,-F ,-Cl ,-Br ,-CN ,-CCH ,-NO
2,-OMe, C
1-C
4alkyl or C
3-C
5cycloalkyl; R
3for-H or C
1-C
4alkyl; X is-Cl ,-Br or-I; R
4for C
1-C
4alkyl.
2. the bromo-imidazo [1 of a class 5-according to claim 1,2-A] synthetic method of pyrimidine-3-carboxylicesters and respective acids thereof, it is characterized in that: described step 1) in reaction carry out in a solvent, solvent used be in methylene dichloride, 1,2-ethylene dichloride, chloroform, tetrahydrofuran (THF), ethyl acetate, acetonitrile, toluene, dimethylbenzene, ether, butanols and Virahol any one.
3. the synthetic method of a class 5-according to claim 1 bromo-imidazo [1,2-A] pyrimidine-3-carboxylicesters and respective acids thereof, is characterized in that: described step 1) in reaction carry out under condition of no solvent.
4. the synthetic method of a class 5-according to claim 1 bromo-imidazo [1,2-A] pyrimidine-3-carboxylicesters and respective acids thereof, is characterized in that: described step 1) in temperature of reaction be 0 ~ 80 DEG C.
5. the bromo-imidazo [1 of a class 5-according to claim 1,2-A] synthetic method of pyrimidine-3-carboxylicesters and respective acids thereof, it is characterized in that: described step 1) method of purification of Chinese style (3) compound is extraction, recrystallization, underpressure distillation or column chromatography.
6. the bromo-imidazo [1 of a class 5-according to claim 1,2-A] synthetic method of pyrimidine-3-carboxylicesters and respective acids thereof, it is characterized in that: described step 2) in reaction carry out in a solvent, solvent used is any one in methylene dichloride, chloroform, tetrahydrofuran (THF), ethyl acetate, acetonitrile, methyl alcohol, ethanol, propyl alcohol, Virahol, butanols, DMF and toluene; Described step 2) in temperature of reaction be 0 ~ 150 DEG C; Described step 2) in method of purification be extraction, recrystallization or column chromatography.
7. the synthetic method of a class 5-according to claim 1 bromo-imidazo [1,2-A] pyrimidine-3-carboxylicesters and respective acids thereof, is characterized in that: described step 3) in temperature of reaction be 15 ~ 90 DEG C.
8. the synthetic method of a class 5-according to claim 1 bromo-imidazo [1,2-A] pyrimidine-3-carboxylicesters and respective acids thereof, is characterized in that: described step 3) in base hydrolysis step alkali used be NaOH, KOH, LiOH or K
3pO
4; The acid used of described acidification step is hydrochloric acid, acetic acid or sulfuric acid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510444388.9A CN105061433A (en) | 2015-07-24 | 2015-07-24 | Synthetic method for 5-bromo-imidazo[1, 2-A]pyrimidine-3-carboxylate and corresponding acid thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510444388.9A CN105061433A (en) | 2015-07-24 | 2015-07-24 | Synthetic method for 5-bromo-imidazo[1, 2-A]pyrimidine-3-carboxylate and corresponding acid thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105061433A true CN105061433A (en) | 2015-11-18 |
Family
ID=54490995
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510444388.9A Pending CN105061433A (en) | 2015-07-24 | 2015-07-24 | Synthetic method for 5-bromo-imidazo[1, 2-A]pyrimidine-3-carboxylate and corresponding acid thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105061433A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012143796A2 (en) * | 2011-04-21 | 2012-10-26 | Institut Pasteur Korea | Anti-inflammation compounds |
| CN103188934A (en) * | 2010-10-18 | 2013-07-03 | 纳幕尔杜邦公司 | Nematocidal sulfonamides |
| CN104193745A (en) * | 2014-07-30 | 2014-12-10 | 天津市斯芬克司药物研发有限公司 | Imidazolopyrimidine carboxylic acid type compound and preparation method thereof |
-
2015
- 2015-07-24 CN CN201510444388.9A patent/CN105061433A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103188934A (en) * | 2010-10-18 | 2013-07-03 | 纳幕尔杜邦公司 | Nematocidal sulfonamides |
| WO2012143796A2 (en) * | 2011-04-21 | 2012-10-26 | Institut Pasteur Korea | Anti-inflammation compounds |
| CN104193745A (en) * | 2014-07-30 | 2014-12-10 | 天津市斯芬克司药物研发有限公司 | Imidazolopyrimidine carboxylic acid type compound and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| SKOF, MARKO等: "The synthesis of azahomotryptophan derivatives. The transformation of N-trifluoroacetyl-5-bromo-4-oxonorvaline methyl ester into 4-(imidazo[1,2-a]azinyl-3)-4-oxohomoalanine derivatives", 《JOURNAL OF HETEROCYCLIC CHEMISTRY》 * |
| 刘举等: "新型咪唑并[1，2-a]嘧啶类化合物的合成", 《合成化学》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101613361B (en) | Method for preparing cefoxitin sodium | |
| CN104974060A (en) | Method for preparing sodium, 8-(2-hydroxybenzamido)octanoate | |
| CN101619069A (en) | Preparation method of cefotiam hexetil hydrochloride | |
| CN106256824A (en) | A kind of preparation method of high-purity De Lasha star meglumine salt | |
| CN104059025A (en) | Novel intermediate used for preparation of avanafil and preparation method thereof | |
| CN101475539B (en) | Refining method for preparing high-purity oteracil potassium | |
| CN103897025B (en) | A kind of preparation method of Pidotimod | |
| CN103965191A (en) | Synthesis method of 6-bromoimidazo[1,2-alpha]pyridyl-3-formic acid | |
| CN108373468B (en) | Preparation method of N-2-pyridine-5-pyrimidine methylamine | |
| CN102093263A (en) | Recycling method of levorotation camphorsulfonic acid serving as clopidogrel resolving agent | |
| CN105061433A (en) | Synthetic method for 5-bromo-imidazo[1, 2-A]pyrimidine-3-carboxylate and corresponding acid thereof | |
| CN103896941A (en) | Synthesis method of 6-chloroimidazo[1,2-a]pyridine-3-formonitrile | |
| CN106749226A (en) | A kind of preparation method of avatrombopag maleates crystal formation C | |
| CN104277053A (en) | High purity cefodizime and preparation method for intermediate cefodizime acid | |
| CN103724358A (en) | Method for preparing (3aS, 6aR)-1, 3-dibenzyl-tetrahydro-4H-thieno [3, 4-d] imidazole-2, 4-(1H)-diketone | |
| CN103772189B (en) | Synthesis method of diethylstilbestrol compound methyl pigeon pea ketonic acid A | |
| CN103159756A (en) | Novel preparation method for nicergoline | |
| CN103588712A (en) | Pyrimidine compound and preparation method and application thereof | |
| CN105585539A (en) | One-pot ceftazidime side-chain acid ethyl ester synthesis method | |
| CN103965190A (en) | Synthesis method of imidazo[1,2-alpha]pyridyl-3-formic acid | |
| CN114702425A (en) | Preparation method of (S) -2-amino- (S) -3- [ pyrrolidone-2' ] alanine derivative and intermediate | |
| CN103739545A (en) | Simple preparation method of vitamin B6 | |
| CN103965192A (en) | Synthesis method of 6-chloroimidazo[1,2-alpha]pyridyl-3-formic acid | |
| CN105503853A (en) | Synthetic method of cefdinir activated thioester | |
| CN102690211B (en) | The preparation method of tolvaptan intermediate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20151118 |